Same allotment. No?
A closer look at Canada's homegrown COVID-19 vaccine candidatesA big article these 2 quotes show the lack of support for our contributions
But Canada has also invested in some COVID-19 vaccines in development here, and there are more than half a dozen Canadian vaccine candidates registered with the World Health Organization (and at least a handful that are not). At least two of the Canadian vaccine candidates are already being tested on humans. The vaccines under development represent a wide range of technologies, from more traditional protein subunit vaccines to newer technologies such as replicating viral vector and DNA vaccines. The options, if approved, would include not just needles, but nasal spray and a vaccine that can be swallowed.
Dr. Volker Gerdts, director and CEO of the Vaccine and Infectious Disease Organization-International Vaccine Centre at the University of Saskatchewan in Saskatoon, argues that "it's very important … to be self-sufficient and have access to vaccines that are being produced here in Canada for Canadians."
The federal government recently invested $1 billion dollars in preorders for seven foreign vaccine candidates, even though there's no guarantee that any of them will ever make it through clinical trials to market.
But some Canadian vaccine developers have reported facing big hurdles in development, including not enough government support. Gerdts said lack of manufacturing capacity in Canada slowed efforts earlier this summer.
Michael Houghton, who is leading a vaccine development team at the University of Alberta, said lack of funding to manufacture vaccines for a clinical trial has set his team back. Providence Therapeutics, a Toronto-based company working on mRNA vaccines against COVID-19, had complained earlier in the year about a lack of government support for clinical trials. However, in October, it received federal funding for human testing. Some other teams, such as Halifax-based IMV and Edmonton-based Entos, have also announced they are getting federal government funding to proceed with clinical trials.